Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c

(NASDAQ Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC)...

Related Keywords

Stockholm ,Sweden ,Prnewswire Cantargia ,Eric Van Cutsem , ,Precision Promise ,Accessory Protein ,Poster Discussion Session ,Gastrointestinal Cancer ,Hepatobiliarysession Date ,Eric Van ,Nasdaq Stockholm ,